# A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

> **NCT07252440** · PHASE2 · RECRUITING · sponsor: **Shanghai Auzone Biological Technology Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- AD
- Early Alzheimer's Disease

## Interventions

- **DRUG:** TTYP01 tables 60mg
- **DRUG:** TTYP01 tables 90mg
- **DRUG:** TTYP01 tables 0mg

## Key facts

- **NCT ID:** NCT07252440
- **Lead sponsor:** Shanghai Auzone Biological Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2028-10-23
- **Final completion:** 2028-11-23
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07252440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07252440, "A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07252440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*